TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Microbix Biosystms ( (TSE:MBX) ) has provided an update.
Microbix Biosystems Inc. has launched new QAPs™ quality assessment products and QUANTDx™ reference materials to support testing for the H3N2 strain of Influenza A, which is experiencing an antigenic drift, affecting immunity and test accuracy. The company’s new products are designed to ensure reliable detection of H3N2 variants, providing stability and accuracy for laboratories and test developers, thus supporting effective public health responses and improving healthcare outcomes globally.
The most recent analyst rating on (TSE:MBX) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Microbix Biosystms stock, see the TSE:MBX Stock Forecast page.
Spark’s Take on TSE:MBX Stock
According to Spark, TipRanks’ AI Analyst, TSE:MBX is a Neutral.
Microbix Biosystems’ overall stock score is primarily influenced by its strong financial performance and stability, despite recent revenue challenges. Technical indicators suggest bearish momentum, and valuation metrics are weak due to a negative P/E ratio. The earnings call reflects both immediate challenges and potential for future growth, balancing the overall outlook.
To see Spark’s full report on TSE:MBX stock, click here.
More about Microbix Biosystms
Microbix Biosystems Inc. is a life sciences company based in Mississauga, Ontario, specializing in the creation of proprietary biological products for human health. With over 120 employees and a revenue of C$ 25.4 million in 2024, the company produces critical ingredients and devices for the global diagnostics industry, including antigens for immunoassays and laboratory quality assessment products (QAPs™) and reference materials (QUANTDx™). These products support clinical lab proficiency testing, assay development, and validation, and ensure the quality of clinical diagnostic workflows. Microbix’s products are available in over 30 countries, and the company is ISO 9001 & 13485 accredited, U.S. FDA registered, and provides IVDR-compliant CE marked products.
Average Trading Volume: 42,469
Technical Sentiment Signal: Sell
Current Market Cap: C$34.05M
For a thorough assessment of MBX stock, go to TipRanks’ Stock Analysis page.